Biling Bio Secures Nearly RMB 200 Million in Series A Financing to Advance Innovative Nanomedicine Pipeline

Recently, Best-link Bioscience announced the completion of its Series A financing round, raising nearly RMB 200 million. The round was led by Longpan Investment, with participation from Huiding Investment and Taiyu Investment, among others. Haoyi Capital served as the exclusive financial advisor. The proceeds will be used to advance preclinical research and development of its existing pipeline, submit Investigational New Drug (IND) applications, progress into Phase I clinical trials, and expand its technology platform.

Dr. Zhang Fuyao, Chairman and General Manager of Best-link BioscienceStatement: We extend our sincere gratitude to Longpan Investment, Huiding Investment, and Taiyu Investment for their strong recognition, and to Haoyi Capital for its professional services. We also thank Yangshengtang Jiaozi Tea Industry, our angel-round investor, for its continued attention and support of Best-link Bioscience. Our appreciation goes to the team for their hard work and dedication. The successful completion of this financing round provides robust support and momentum for Best-link Bioscience to accelerate the advancement of its existing R&D pipeline into clinical studies.Over the past year and more, despite the capital winter, the company has relied on its solid technical reserves and R&D resources to address unmet clinical needs. We have built a drug R&D pipeline and technology platform with core competitiveness and differentiation, achieving remarkable results in team building and project advancement. The core team of Best-link Bioscience will adhere to a R&D strategy focused on frontier innovation and differentiated layout. We will explore an innovative drug development model characterized by the integration of “four new elements”: new materials, new technologies, new equipment, and new drugs. With focused research, careful planning, and wholehearted commitment, we aim to develop high-quality medicines for patients, generate returns for investors, and drive sustainable growth for the company.

Yu Zhihua, Chairman of Longpan InvestmentStatement: Best-link Bioscience is an innovative drug R&D company with tremendous growth potential. We were deeply impressed by Dr. Zhang, the founder, and his team’s profound expertise in nanomedicines and conjugate drugs, as well as their strong capability in product translation. The company’s independently developed nano-self-assembly platform has demonstrated excellent druggability and scalability, along with encouraging preclinical data. We are delighted to participate in Best-link Bioscience’s development through investment, and we will leverage our resources and experience to further support the founding team in driving the company’s growth. We look forward to seeing Best-link Bioscience’s products enter clinical use at an early stage, thereby providing better treatment options for patients in China and around the world.

Dr. He Xin, Managing Partner of Huiding Investment ManagementStatement: We are delighted to have the opportunity to support the development of Best-link Bioscience through this round of investment. Leveraging its profound understanding of nanomedicines, Best-link Bioscience focuses on unmet clinical needs and independently develops innovative drugs with internationally leading capabilities. Amidst the broader challenges facing China’s innovative drug industry, Best-link Bioscience’s global innovation capacity, efficient team execution, highly synergistic pipeline layout, and compelling data strongly demonstrate the company’s value and growth potential. Huiding Investment is committed to assisting enterprises with global technological innovations in their growth. We are very optimistic about Best-link Bioscience’s future R&D progress and clinical advancement, and look forward to providing robust post-investment support to facilitate its greater development.

Dr. Ji Tianrong, Founder & General Manager of Taiyu InvestmentStatement: The team members of Shanghai Best-link Bioscience possess over 20 years of experience in the R&D of antibody-drug conjugates (ADCs) and pharmaceutical company management. Leveraging their independently developed NPDC conjugation self-assembly technology platform, they have achieved enhanced tumor penetration and reduced immunogenicity while maintaining target specificity. Preclinical studies have demonstrated favorable efficacy and safety profiles. The company hopes to bring its innovative nanomedicines to market at an early date, thereby benefiting a broader patient population.

Wen Baoying, Partner at Haoyi CapitalStatement: Congratulations to Best-link Bioscience on completing its latest round of financing. Leveraging its profound understanding and years of research in self-assembling nanotechnology, Best-link Bioscience has built a novel technology platform and developed self-assembling nanomedicines with core differentiation and innovation. These drugs not only retain the relevant characteristics of nanomedicines but also feature high drug-loading capacity while avoiding side effects such as carrier-induced toxicity and immunogenicity, demonstrating significant market potential in the field of drug development. We are honored to have participated in and facilitated this financing round throughout the process, and we look forward to this funding substantially accelerating Best-link Bioscience’s R&D progress, ushering in a new chapter in innovative drug development.

Shanghai Best-link Bioscience, LLC was established in May 2021. It is a high-tech enterprise centered on the R&D of innovative nanomedicines and precise drug delivery. The company’s founder possesses many years of R&D and management experience at major pharmaceutical companies both internationally and domestically, while its management team has extensive experience in new drug development as well as working in markets both within China and overseas.

As a biopharmaceutical company dedicated to the research and development of novel nanomedicines and precision nano-delivery systems, Best-link Bioscience has assembled a multidisciplinary R&D team integrating expertise in biology, chemistry, materials science, engineering, and nanotechnology. The company has established internationally pioneering platforms, including a drug conjugate self-assembling nanotechnology platform, a small molecule-small molecule self-assembling nanotechnology platform, and a continuous intelligent manufacturing platform for nanomedicines. By covering everything from nanomaterials to nano-formulation processes and equipment, Best-link Bioscience has overcome multiple technical barriers across the entire spectrum of nanomedicine research, translation, and production. Leveraging its proprietary high-throughput continuous manufacturing processes and equipment, the company achieves scalable, continuous production of nanomedicines with stepwise amplification capability, ensuring stable and controllable product quality.

Guided by the philosophy of “Empowering Health, Leading the Future,” the company is dedicated to developing innovative drugs with higher efficacy, better safety, and improved compliance through the integration of new materials, new technologies, new equipment, and new drugs. It strives to build a differentiated and globally innovative drug R&D pipeline. The company has filed more than 10 invention patent applications through independent R&D, with several patents already granted in China, the United States, Europe, Japan, and other countries and regions. Additionally, multiple new drug projects have entered the preclinical research stage, and two candidates in the R&D pipeline have reached the Investigational New Drug (IND) application stage.

LongPan Investment, headquartered in Beijing, is a leading biomedical venture capital firm in China. Currently, LongPan Investment manages five RMB-denominated funds and one USD-denominated fund, with total assets under management exceeding RMB 10 billion. It is the only biomedical investment institution to date that has received capital commitments from both of China’s top two RMB limited partners: the National Council for Social Security Fund and the National Small and Medium Enterprises Development Fund. LongPan Investment focuses on innovative drugs and innovative medical devices, primarily investing at the seed, early, and growth stages. To date, it has invested in more than 70 innovative drug companies and over 20 innovative medical device companies, including numerous standout portfolio companies such as Beta Pharma (SZ.300558), RemeGen (SH.688331), Yihua Pharmaceutical (SH.688176), Swabio, BinHui Biotech, ImmuneOnco, Huahao Zhongtian, and Aier Eye Hospital Group’s subsidiary Aibo Medical (SH.688050). Many partners in LongPan Investment’s management team possess over 20 years of R&D and management experience in the international and domestic biomedical industries, enabling them to provide comprehensive value-added services to portfolio companies.

Huiding Investment brings together a team of senior partners from China’s leading investment institutions, founded by professionals with extensive experience in startup operations, overseas technology localization in China, and industry resources. Committed to integrating global technological innovations and focusing on the upgrading of China’s healthcare industry, Huiding leverages its accumulated clinical and industry expertise to drive enterprise growth. The firm maintains a deep vertical focus on high-growth, high-barrier sectors such as immunology, regenerative medicine, and precision medicine, aiming to pool resources and provide robust support to help Chinese companies emerge as industry leaders.

Taiyu Investment, established in 2014, is an independent venture capital firm under Tigermed. Taiyu Investment focuses on equity investments in early-stage and growth-stage companies within the healthcare sector. Its management team boasts extensive industry expertise, broad sector resources, and rich investment experience. To date, it has completed investments totaling RMB 2 billion across nearly 100 projects, with a portfolio spanning medical devices, biopharmaceuticals, CROs, and health supplements. By empowering its portfolio companies, Taiyu Investment creates value for the development of the healthcare industry in China and globally, contributing to public health.

Hao Yi Capital, established in 2020, is a boutique investment bank focused on the healthcare sector. It is dedicated to identifying promising early-stage startups with unique potential in the medical field, leveraging its expertise, insights, skills, and experience to help these companies transcend their limits and break through uncertainties. We continuously seek opportunities for industrial upgrading within the pharmaceutical and healthcare industries. By drawing on Hao Yi’s extensive industry experience and resource network, we provide premium enterprises in the pharmaceutical sector with services such as financing, mergers and acquisitions, and project transactions, growing alongside exceptional entrepreneurs.